![Wilfried van Langenaeker](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Wilfried van Langenaeker
Nessuna posizione attualmente
Storia della carriera di Wilfried van Langenaeker
Precedenti posizioni note di Wilfried van Langenaeker
Società | Posizione | Inizio | Fine |
---|---|---|---|
Silicos SA
![]() Silicos SA Pharmaceuticals: MajorHealth Technology Silicos, founded in June 2005, is a chemo-informatics-based biotechnology company empowering proprietary multi-target virtual screening technologies for the discovery of novel and high-quality lead compounds for the treatment of a large variety of diseases, such as cancer, infectious diseases, central nervous system and immunodeficiency diseases. Silicos' proprietary virtual screening technology is based on a unique concept called Spectrophores™, which are descriptors representing all possible three-dimensional molecular properties involved in the binding of a drug to its receptor. Cosmos™ is Silicos' platform for the de novo design of new small molecules optimized towards one or multiple targets. | Fondatore | 28/08/2009 | 11/05/2012 |
Presidente | 01/01/2005 | 11/05/2012 | |
The University of North Carolina at Charlotte | Corporate Officer/Principal | - | - |
Formazione di Wilfried van Langenaeker
Université Libre de Bruxelles | Undergraduate Degree |
Statistiche
Distribuzione geografica
Belgio | 3 |
Stati Uniti | 2 |
Posizioni
Founder | 1 |
President | 1 |
Undergraduate Degree | 1 |
Settori
Consumer Services | 3 |
Health Technology | 2 |
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Società collegate
Aziende private | 1 |
---|---|
Silicos SA
![]() Silicos SA Pharmaceuticals: MajorHealth Technology Silicos, founded in June 2005, is a chemo-informatics-based biotechnology company empowering proprietary multi-target virtual screening technologies for the discovery of novel and high-quality lead compounds for the treatment of a large variety of diseases, such as cancer, infectious diseases, central nervous system and immunodeficiency diseases. Silicos' proprietary virtual screening technology is based on a unique concept called Spectrophores™, which are descriptors representing all possible three-dimensional molecular properties involved in the binding of a drug to its receptor. Cosmos™ is Silicos' platform for the de novo design of new small molecules optimized towards one or multiple targets. | Health Technology |